25.07.2014 • News • Dede Willams • Merck • Merck Serono

Merck Serono Extends Italian Alliance for Neurodegenerative Diseases

Merck Serono, the biopharmaceuticals arm of Germany's Merck KgaA, is extending by two years its 10-year R&D cooperation with San Raffaele University & Research Hospital for Research in Milan focusing on neurodegenerative diseases.

The partners are aiming at the development of pre-clinical and clinical research projects with a focus on developing innovative therapies against serious and disabling neurological diseases such as multiple sclerosis affecting young adults in particular.

San Raffaele University & Research Hospital are providing know-how and laboratories to develop new therapies and to evaluate the effectiveness of the molecules developed by Merck Serono.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Top-Feature

most read

Photo
28.07.2025 • News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.